Skip to content

Adipocytokine levels in obese children before and after lifestyle intervention

Investigations of levels of adiponectin, leptin, and CRP in a cohort of 11-13-years old children before and after a lifestyle intervention program.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN71948313
Enrollment
30
Registered
2015-09-10
Start date
2009-09-01
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity Nutritional, Metabolic, Endocrine Obesity

Interventions

The children and their families are followed at the out-patient clinic at the Pediatric Department at 7 consultations during one year. Three visits are individual and included physical examination by

Sponsors

Regional Hospital Viborg
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged between 11-13 years 2. BMI = 22 (this value at the age of 12 years old correlates to BMI of 25 in an adult)

Exclusion criteria

Exclusion criteria: Considerable comorbidity which would make participation in structural physical activity impossible.

Design outcomes

Primary

MeasureTime frame
1. The degree of weight loss and weight changes. Weight, height and BMI was registrated every third month during the intervention period. 2. Changes in adiponectin, leptin and c-reactive protein (CRP) are measured before and after the intervention. Adiponectin (mg/l) is determined by a validated in-house time-resolved immunofluorometric assay based on two monoclonal antibodies and recombinant human adiponectin (obtained from R&D Systems, Abingdon, UK). Leptin (µg/l) is determined by a validated in-house time-resolved immunofluorometric assay based on commercial available monoclonal antibodies and recombinant human leptin (R&D Systems, Abingdon, UK). CRP levels are determined by a high sensitive CRP (hsCRP) TRIFMA assay based on commercial available monoclonal antibodies (R&D systems).

Secondary

MeasureTime frame
1. Waist circumference, measured every third month during the intervention. 2. Hip circumference, measured every third month during the intervention. 3. Blood pressure, measured every third month during the intervention.

Countries

Denmark

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026